Compare AA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | RPRX |
|---|---|---|
| Founded | 1888 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 16.4B |
| IPO Year | 2016 | 2020 |
| Metric | AA | RPRX |
|---|---|---|
| Price | $53.88 | $39.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $42.32 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 6.0M | 3.7M |
| Earning Date | 01-22-2026 | 02-10-2026 |
| Dividend Yield | 0.74% | ★ 2.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.31 | 1.75 |
| Revenue | ★ $12,868,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $9.84 | $37.66 |
| Revenue Next Year | $6.10 | $2.34 |
| P/E Ratio | ★ $12.59 | $22.39 |
| Revenue Growth | ★ 16.94 | 3.70 |
| 52 Week Low | $21.53 | $25.16 |
| 52 Week High | $54.43 | $41.24 |
| Indicator | AA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 77.74 | 53.12 |
| Support Level | $53.00 | $38.20 |
| Resistance Level | $54.43 | $39.50 |
| Average True Range (ATR) | 1.71 | 0.62 |
| MACD | 0.62 | 0.02 |
| Stochastic Oscillator | 95.29 | 74.25 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is the world's largest bauxite miner and alumina refiner by production volume, and the eighth-largest aluminum producer. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024, meaning refining assets are now predominantly wholly owned, as with smelting.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.